[1] Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013, 137(1):89-99. DOI: 10.1016/j.pharmthera.2012.09.003.
[2] Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma[J]. N Engl J Med, 2021, 385(22):2066-2076. DOI: 10.1056/NEJMra2103423.
[3] Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols[J]. J Clin Oncol, 2003, 21(10):2011-2018. DOI: 10.1200/JCO.2003.08.132.
[4] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002, 20(3):776-790. DOI: 10.1200/JCO.2002.20.3.776.
[5] Mustafa M, Iftikhar H, IIIzam E, et al. Osteosarcoma: current treatment trends and outcome[J]. IOSR Journal of Dental and Medical Sciences, 2018, 17(11): 32-38. DOI:10.9790/0853-1711023238.
[6] Hattinger CM, Patrizio MP, Fantoni L, et al. Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies[J]. Cancers (Basel), 2021, 13(12):2878. DOI: 10.3390/cancers13122878.
[7] Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma[J]. Clin Orthop Relat Res, 1980(153):106-120.
[8] Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases[J]. Ann Surg Oncol, 2014, 21(1):263-268. DOI: 10.1245/s10434-013-3210-4.
[9] Jauregui JJ, Nadarajah V, Munn J, et al. Limb salvage versus amputation in conventional appendicular osteosarcoma: a systematic review[J]. Indian J Surg Oncol, 2018, 9(2):232-240. DOI: 10.1007/s13193-018-0725-y.
[10] Odri GA, Tchicaya-Bouanga J, Yoon DJY, et al. Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers[J]. Cancers (Basel), 2022, 14(2):360. DOI: 10.3390/cancers14020360.
[11] Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy[J]. Nat Rev Endocrinol, 2017, 13(8):480-491. DOI: 10.1038/nrendo.2017.16.
[12] Chen C, Xie L, Ren T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs[J]. Cancer Lett, 2021, 500:1-10. DOI: 10.1016/j.canlet.2020.12.024.
[13] Peng Z, Li M, Wang Y, et al. Self-assembling imageable silk hydrogels for the focal treatment of osteosarcoma[J]. Front Cell Dev Biol, 2022, 10:698282. DOI: 10.3389/fcell.2022.698282.
[14] Benjamin RS. Adjuvant and neoadjuvant chemotherapy for osteosarcoma: a historical perspective[J]. Adv Exp Med Biol, 2020, 1257:1-10. DOI: 10.1007/978-3-030-43032-0_1.
[15] Zheng C, Tang F, Min L, et al. PTEN in osteosarcoma: recent advances and the therapeutic potential[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2):188405. DOI: 10.1016/j.bbcan.2020.188405.
[16] Yang D, Xu T, Fan L, et al. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis[J]. J Exp Clin Cancer Res, 2020, 39(1):201. DOI: 10.1186/s13046-020-01670-3.
[17] Rabelo ACS, Borghesi J, Noratto GD. The role of dietary polyphenols in osteosarcoma: a possible clue about the molecular mechanisms involved in a process that is just in its infancy[J]. J Food Biochem, 2022, 46(1):e14026. DOI: 10.1111/jfbc.14026.
[18] Smrke A, Anderson PM, Gulia A, et al. Future directions in the treatment of osteosarcoma[J]. Cells, 2021, 10(1):172. DOI: 10.3390/cells10010172.
[19] Lettieri CK, Appel N, Labban N, et al. Progress and opportunities for immune therapeutics in osteosarcoma[J]. Immunotherapy, 2016, 8(10):1233-1244. DOI: 10.2217/imt-2016-0048.
[20] Wang Z, Li B, Ren Y, et al. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities[J]. Front Immunol, 2016, 7:353. DOI: 10.3389/fimmu.2016.00353.
[21] Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy[J]. Nature, 2019, 574(7776):45-56. DOI: 10.1038/s41586-019-1593-5.
[22] Corre I, Verrecchia F, Crenn V, et al. The osteosarcoma microenvironment: a complex but targetable ecosystem[J]. Cells, 2020, 9(4):976. DOI: 10.3390/cells9040976.
[23] Yoshida K, Okamoto M, Sasaki J, et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells[J]. BMC Cancer, 2020, 20(1):25. DOI: 10.1186/s12885-019- 6499-y.
[24] Wedekind MF, Wagner LM, Cripe TP. Immunotherapy for osteosarcoma: where do we go from here?[J]. Pediatr Blood Cancer, 2018, 65(9):e27227. DOI: 10.1002/pbc.27227.
[25] Wang L, Mei Q, Xie Q, et al. A comparative study of Mesenchymal Stem Cells transplantation approach to antagonize age-associated ovarian hypofunction with consideration of safety and efficiency[J]. J Adv Res, 2021, 38:245-259. DOI: 10.1016/j.jare.2021.09.001.
[26] Hammad M, Cornejo YR, Batalla-Covello J, et al. Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model[J]. Mol Ther Oncolytics, 2020, 18:326-334. DOI: 10.1016/j.omto.2020.07.002.
[27] Yu W, Zhu J, Wang Y, et al. A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep[J]. Oncotarget, 2017, 8(24):39833-39848. DOI: 10.18632/oncotarget. 16243.
[28] Tan G, Xu J, Yu Q, et al. The safety and efficiency of photodynamic therapy for the treatment of osteosarcoma: a systematic review of in vitro experiment and animal model reports[J]. Photodiagnosis Photodyn Ther, 2022, 40:103093. DOI: 10.1016/j.pdpdt.2022. 103093.
[29] Barani M, Mukhtar M, Rahdar A, et al. Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma[J]. Biosensors (Basel), 2021, 11(2):55. DOI: 10.3390/bios11020055.
[30] Yu W, Ye M, Zhu J, et al. Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma[J]. Nanomedicine, 2018, 14(4):1099-1110. DOI: 10.1016/j.nano.2018.02.005.
|